KLOW Blend Research Peptides

Compare KLOW blend research products by labelled quantity, price per mg, testing evidence and product transparency. See what’s available from suppliers and use our comparison tools to make more informed decisions.

Research-use products only. Not presented as supplements, medicines, or products for human or veterinary consumption.

4products compared

1labelled quantities

£0.66 – £0.94per mg

1with verified testing evidence

Top Picks

Best Overall

Quantity: 80 mg / vial

£0.87per mg

£69.99per pack

View Analysis Buy Now

Product & testing details

Supplier: UK Peptides (ukpeptides.org)
Vials per pack: 1
Price per vial: £69.99
Listing last checked: 2026-09-22 11:25:55

Evidence status: Verified independent evidence
Manufacturer statement: "Independently tested · accredited external lab"; "Third-party HPLC-UV testing"; "Lot-matched COAs published"; "Independent third-party laboratory report for batch 2026-07-15 of KLOW 80mg, issued by an accredited independent laboratory using HPLC-UV + Mass Spectrometry. Result: ≥98% HPLC (all components)."
Laboratory: MZ Biolabs
Certification body: Not recorded
Batch: 2026-07-15
Batch-specific report: Recorded
Report date: 2026-07-31
Evidence checked: 2026-09-22

Certificate of analysis ↗

KLOW 80mg

UK Peptides (ukpeptides.org)

£0.87per mg

£69.99per pack

View Analysis Buy Now

Best Tested

Quantity: 80 mg / vial

£0.87per mg

£69.99per pack

View Analysis Buy Now

Product & testing details

Supplier: UK Peptides (ukpeptides.org)
Vials per pack: 1
Price per vial: £69.99
Listing last checked: 2026-09-22 11:25:55

Evidence status: Verified independent evidence
Manufacturer statement: "Independently tested · accredited external lab"; "Third-party HPLC-UV testing"; "Lot-matched COAs published"; "Independent third-party laboratory report for batch 2026-07-15 of KLOW 80mg, issued by an accredited independent laboratory using HPLC-UV + Mass Spectrometry. Result: ≥98% HPLC (all components)."
Laboratory: MZ Biolabs
Certification body: Not recorded
Batch: 2026-07-15
Batch-specific report: Recorded
Report date: 2026-07-31
Evidence checked: 2026-09-22

Certificate of analysis ↗

KLOW 80mg

UK Peptides (ukpeptides.org)

£0.87per mg

£69.99per pack

View Analysis Buy Now

Lowest Price per mg

Quantity: 80 mg / vial

£0.66per mg

£52.99per pack

View Analysis Buy Now

Product & testing details

Supplier: Owsa Labs
Vials per pack: 1
Price per vial: £52.99
Listing last checked: 2026-09-22 11:04:33

Evidence status: Testing claimed
Manufacturer statement: Product page: "Certificate of Analysis"; "Third-party tested"; "Tested for peptide content and purity by Janoshik Analytical." Testing page: "We publish Janoshik reports when we have them for the lot we ship."; "Identity — mass spectrometry" and "Purity — high-performance liquid chromatography."
Laboratory: Janoshik Analytical
Certification body: Not recorded
Batch: Not recorded
Batch-specific report: Not established in this record
Report date: Not recorded
Evidence checked: 2026-09-22

KLOW Blend — 80 mg

Owsa Labs

£0.66per mg

£52.99per pack

View Analysis Buy Now

Compare research products

Vial size

Research peptide product comparison
#	Product	Quantity	Price / vial	Price / mg	Testing	Score
1	KLOW 80mgUK Peptides (ukpeptides.org)	80 mg / vial	£69.99per vial	£0.87per mg	Testing evidence Evidence status Verified independent evidence Manufacturer statement "Independently tested · accredited external lab"; "Third-party HPLC-UV testing"; "Lot-matched COAs published"; "Independent third-party laboratory report for batch 2026-07-15 of KLOW 80mg, issued by an accredited independent laboratory using HPLC-UV + Mass Spectrometry. Result: ≥98% HPLC (all components)." Laboratory MZ Biolabs Certification body Not recorded Batch 2026-07-15 Batch-specific report Recorded Report date 2026-07-31 Evidence checked 2026-09-22 Certificate of analysis ↗	Why this score? Testing & analytical evidence 36/45 Value 15/25 Product identity 12/15 Supplier transparency 10/10 Label & listing transparency 5/5 Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.	Buy Now
2	KLOW 80mgReta Research	80 mg / vial	£55.00per vial	£0.69per mg	Testing evidence Evidence status Testing claimed Manufacturer statement Supplied as an 80mg combined formulation, ≥99% purity by HPLC, Certificate of Analysis on request. Research-grade peptides, independently HPLC-tested and dispatched fast across the UK. Every batch is published per batch and the site says it is independently verified. Laboratory Not recorded Certification body Not recorded Batch Not recorded Batch-specific report Not established in this record Report date Not recorded Evidence checked 2026-09-22	Why this score? Testing & analytical evidence 10/45 Value 19/25 Product identity 12/15 Supplier transparency 10/10 Label & listing transparency 5/5 Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.	Buy Now
3	KLOW Blend 80mgPepSource	80 mg / vial	£75.00per vial	£0.94per mg	Testing evidence Evidence status Testing claimed Manufacturer statement "Every batch is independently third-party tested for HPLC purity and mass-spectrometry identity, and the certificate of analysis for the batch you receive is published on our lab results page." Laboratory Janoshik Analytical Certification body Not recorded Batch Not recorded Batch-specific report Not established in this record Report date Not recorded Evidence checked 2026-09-22	Why this score? Testing & analytical evidence 10/45 Value 14/25 Product identity 13/15 Supplier transparency 10/10 Label & listing transparency 5/5 Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.	Buy Now
4	KLOW Blend — 80 mgOwsa Labs	80 mg / vial	£52.99per vial	£0.66per mg	Testing evidence Evidence status Testing claimed Manufacturer statement Product page: "Certificate of Analysis"; "Third-party tested"; "Tested for peptide content and purity by Janoshik Analytical." Testing page: "We publish Janoshik reports when we have them for the lot we ship."; "Identity — mass spectrometry" and "Purity — high-performance liquid chromatography." Laboratory Janoshik Analytical Certification body Not recorded Batch Not recorded Batch-specific report Not established in this record Report date Not recorded Evidence checked 2026-09-22	Why this score? Testing & analytical evidence 10/45 Value 19/25 Product identity 12/15 Supplier transparency 3/10 Label & listing transparency 5/5 Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.	Buy Now

Quantity: 80 mg / vial

£0.87per mg

£69.99per pack

View Analysis Buy Now

Product & testing details

Supplier: UK Peptides (ukpeptides.org)
Vials per pack: 1
Price per vial: £69.99
Listing last checked: 2026-09-22 11:25:55

Evidence status: Verified independent evidence
Manufacturer statement: "Independently tested · accredited external lab"; "Third-party HPLC-UV testing"; "Lot-matched COAs published"; "Independent third-party laboratory report for batch 2026-07-15 of KLOW 80mg, issued by an accredited independent laboratory using HPLC-UV + Mass Spectrometry. Result: ≥98% HPLC (all components)."
Laboratory: MZ Biolabs
Certification body: Not recorded
Batch: 2026-07-15
Batch-specific report: Recorded
Report date: 2026-07-31
Evidence checked: 2026-09-22

Certificate of analysis ↗

Quantity: 80 mg / vial

£0.69per mg

£55.00per pack

View Analysis Buy Now

Product & testing details

Supplier: Reta Research
Vials per pack: 1
Price per vial: £55.00
Listing last checked: 2026-09-22 11:04:33

Evidence status: Testing claimed
Manufacturer statement: Supplied as an 80mg combined formulation, ≥99% purity by HPLC, Certificate of Analysis on request. Research-grade peptides, independently HPLC-tested and dispatched fast across the UK. Every batch is published per batch and the site says it is independently verified.
Laboratory: Not recorded
Certification body: Not recorded
Batch: Not recorded
Batch-specific report: Not established in this record
Report date: Not recorded
Evidence checked: 2026-09-22

Quantity: 80 mg / vial

£0.94per mg

£75.00per pack

View Analysis Buy Now

Product & testing details

Supplier: PepSource
Vials per pack: 1
Price per vial: £75.00
Listing last checked: 2026-09-22 11:04:33

Evidence status: Testing claimed
Manufacturer statement: "Every batch is independently third-party tested for HPLC purity and mass-spectrometry identity, and the certificate of analysis for the batch you receive is published on our lab results page."
Laboratory: Janoshik Analytical
Certification body: Not recorded
Batch: Not recorded
Batch-specific report: Not established in this record
Report date: Not recorded
Evidence checked: 2026-09-22

Quantity: 80 mg / vial

£0.66per mg

£52.99per pack

View Analysis Buy Now

Product & testing details

Supplier: Owsa Labs
Vials per pack: 1
Price per vial: £52.99
Listing last checked: 2026-09-22 11:04:33

Evidence status: Testing claimed
Manufacturer statement: Product page: "Certificate of Analysis"; "Third-party tested"; "Tested for peptide content and purity by Janoshik Analytical." Testing page: "We publish Janoshik reports when we have them for the lot we ship."; "Identity — mass spectrometry" and "Purity — high-performance liquid chromatography."
Laboratory: Janoshik Analytical
Certification body: Not recorded
Batch: Not recorded
Batch-specific report: Not established in this record
Report date: Not recorded
Evidence checked: 2026-09-22

What does the KLOW name refer to?

KLOW is a supplier and community name for a blend rather than a recognised chemical entity. The UK listings reviewed most often combine the three compounds sold as GLOW — BPC-157, TB-500 and GHK-Cu — with KPV as a fourth component. Several suppliers state an 80 mg total made up of 50 mg GHK-Cu and 10 mg each of BPC-157, TB-500 and KPV. However, the name itself does not guarantee that ratio, component form, analytical identity or batch composition. [S22] [S23] [S24] [S26]

Evidence snapshot

BPC-157 remains predominantly preclinical in the musculoskeletal literature: a 2025 systematic review included 35 preclinical studies and one human clinical study through June 2024, with no clinical safety data identified. [S2]
The closest direct combination evidence is a 2026 rat Achilles-tendon study of BPC-157 + TB-500. The authors concluded that combining those two did not provide additional benefit over either agent alone. KPV and GHK-Cu were not part of that experiment. [S3]
KPV has substantial laboratory and animal inflammation research, including intestinal-cell experiments and mouse colitis models, but FDA's 2026 review found no human exposure data for KPV by any route. [S13] [S14] [S17]
GHK-Cu has human topical wound and skin studies, but those results apply to the tested topical formulations. They do not establish the effect or safety of a four-component co-formulated research vial. [S9] [S10] [S11]

View sources and methodology →

Quick facts

Blend type: Commercial four-component research-blend name rather than a standardised scientific formulation. [S22] [S23] [S24] [S26]
Common composition observed: UK listings reviewed commonly name GHK-Cu, BPC-157, TB-500 and KPV; several disclose 50 mg GHK-Cu plus 10 mg of each other component, for 80 mg total. [S22] [S23] [S24]
KPV identity: KPV is the free-acid tripeptide Lys-Pro-Val (KPV), corresponding to α-MSH residues 11–13; KPV acetate is a distinct bulk substance/form. [S12] [S17]
KPV human evidence: FDA's 2026 review did not identify clinical studies or human exposure data for KPV free base or KPV acetate by any route. [S17] [S18]
Direct KLOW evidence: No primary human, animal or laboratory study of the exact BPC-157 + TB-500 + GHK-Cu + KPV mixture was located in the targeted searches for this review. [S2] [S17]
Sport context: BPC-157 is prohibited under WADA S0, while thymosin-β4 and its derivatives including TB-500 are prohibited under S2.3. [S19]

One UK listing reviewed contained internally inconsistent wording about component amounts versus an 80 mg total. Check the stated amount of each component against the total rather than relying on the blend name. [S25]

The four component identities must be verified separately

KLOW combines four chemically distinct materials. BPC-157 is a 15-residue peptide. The TB-500 name is associated in analytical literature and PubChem with N-acetylated LKKTETQ, the 17–23 region of thymosin beta-4, but supplier terminology can blur this with full-length thymosin beta-4. GHK-Cu is the copper complex of the GHK tripeptide rather than copper-free GHK. KPV is the free-acid tripeptide H-Lys-Pro-Val-OH, corresponding to α-MSH(11–13); FDA separately evaluates KPV free base and KPV acetate. [S1] [S4] [S5] [S7] [S8] [S12] [S17]

Component / related name	Verified distinction	Evidence handling
BPC-157	15-residue peptide GEPPPGKPADDAGLV.	Single-ingredient findings do not establish KLOW outcomes. [S1]
TB-500	Analytical literature identified Ac-LKKTETQ, the N-acetylated Tβ4 17–23 fragment, in a marketed TB-500 product.	Require product-level identity; do not silently equate with full-length thymosin beta-4. [S4] [S5]
Full-length thymosin beta-4	Separate 43-residue peptide used in human programmes such as RGN-259 ophthalmic trials.	Full-length Tβ4 clinical evidence is not TB-500-fragment or KLOW evidence. [S6]
GHK	Copper-free glycyl-L-histidyl-L-lysine tripeptide.	Do not treat GHK and GHK-Cu as the same analyte or intervention. [S7]
GHK-Cu	Copper complex of GHK.	Topical GHK-Cu results remain formulation- and route-specific. [S8]
KPV	H-Lys-Pro-Val-OH; α-MSH(11–13) free-acid tripeptide.	Free KPV evidence does not automatically transfer to acetate salts, conjugates or delivery systems. [S12] [S17]
KPV acetate	KPV active moiety supplied as an acetate-containing bulk substance/form considered separately by FDA.	Do not assume free-base and acetate product characteristics are interchangeable. [S17]

KPV is related to α-MSH because it corresponds to its C-terminal residues 11–13. That relationship does not make α-MSH studies KPV studies.

Individual ingredient research does not become KLOW evidence

The four ingredients have markedly different evidence bases. BPC-157 has extensive animal research but little human clinical evidence. TB-500 fragment research is much thinner than the literature for full-length thymosin beta-4. GHK-Cu has human topical wound and skin studies. KPV has mechanistic, cell and animal inflammation research, but FDA's 2026 evidence review found no human KPV exposure data. Combining these literatures does not establish an average level of evidence for KLOW. [S2] [S4] [S9] [S10] [S13] [S14] [S17]

BPC-157

A 2025 systematic review included 35 preclinical musculoskeletal studies and one human clinical study through June 2024; no clinical safety data were found. [S2]

Mostly preclinical

TB-500

Identity is a major limitation. Direct fragment evidence should be separated from full-length thymosin beta-4 human trials. [S4] [S5] [S6]

Identity-sensitive

GHK-Cu

Human topical wound and post-procedure skin studies exist, but route and formulation differ from a co-formulated research blend. [S9] [S10] [S11]

Human topical evidence

KPV

Cell and animal inflammation research exists; FDA did not identify clinical studies or human exposure data for free KPV or KPV acetate. [S13] [S14] [S15] [S17]

Preclinical only in reviewed evidence

Ingredient	Human evidence located	Main limitation for KLOW
BPC-157	Sparse low-level human musculoskeletal evidence; old phase-1 registry record has no posted results.	Does not establish four-way efficacy or safety. [S2] [S27]
TB-500 fragment	No robust therapeutic human evidence established in the sources reviewed.	Full-length Tβ4 trials are a different entity. [S4] [S6]
GHK-Cu	Topical human wound/skin trials.	Topical evidence does not establish a mixed-vial or systemic effect. [S9] [S10]
KPV	FDA found no clinical studies or human exposure data by any route.	All efficacy claims for human KLOW that depend on KPV are extrapolations. [S17] [S18]

The addition of KPV to GLOW does not create evidence of improved effectiveness or safety unless the resulting four-component formulation is actually studied.

What KPV research does and does not establish

KPV is one of the clearest differences between GLOW and KLOW, so its evidence needs independent scrutiny. In vitro work has used human intestinal epithelial and T-cell lines and reported reduced NF-κB/MAP-kinase signalling and cytokine secretion, while mouse studies have reported reduced inflammatory measures in chemically induced colitis. Separate mouse work found anti-inflammatory effects in other experimental models. These are mechanistic and preclinical findings. They do not establish efficacy for inflammatory bowel disease, wound healing, skin disease or systemic inflammation in humans. [S13] [S14] [S15] [S17]

Cell models

Human intestinal epithelial cell lines and Jurkat T cells were used to study PepT1-mediated uptake and inflammatory signalling. [S13]

Laboratory evidence

Mouse colitis

KPV reduced histological and inflammatory measures in several chemically induced or transfer-colitis mouse models. [S13] [S14]

Animal evidence

Other inflammation models

Mouse peritonitis research supports anti-inflammatory activity but suggests mechanisms distinct from classic melanocortin-receptor signalling. [S15]

Animal/mechanistic

Human outcomes

FDA's 2026 review did not identify human exposure data or clinical studies for KPV by any route. [S17] [S18]

Not established

KPV research context	What was studied	What it cannot establish
Free KPV in cell systems	Inflammatory signalling, cytokine secretion and PepT1-mediated uptake.	Human clinical benefit. [S13]
Free KPV in mouse colitis	Weight, histology, inflammatory markers and disease-model outcomes.	Efficacy or safety in people. [S13] [S14]
Nanoparticle/hydrogel KPV	Targeted oral delivery and colitis outcomes in mice.	Equivalence to free KPV or KPV contained in KLOW. [S16]
KPV free base vs acetate	FDA evaluated them as distinct bulk drug substances/forms.	Interchangeable formulation quality or human safety. [S17]

A delivery system can materially change where KPV is released and how much reaches a target tissue. Results from nanoparticle or hydrogel formulations should not be assigned to free KPV in a four-component blend.

What is known about combinations containing KLOW ingredients?

The strongest directly relevant combination study located tested only BPC-157 and TB-500. In 32 rats with repaired Achilles tendons, the authors compared control, BPC-157, TB-500 and BPC-157 + TB-500 and concluded that combining the two did not provide additional benefit over either agent alone. No primary study of BPC-157 + GHK-Cu, BPC-157 + KPV, TB-500 + KPV, GHK-Cu + KPV, the GLOW trio plus KPV, or the complete KLOW mixture was located in the targeted searches. [S3]

BPC-157 + TB-500

Direct controlled rat evidence exists; no additional combination benefit was reported. [S3]

Preclinical pair evidence

KPV-containing KLOW pairs

No primary study co-administering KPV with a KLOW component in the commercial blend format was located. [S17]

Not located

GLOW trio

No controlled primary study of the exact BPC-157 + TB-500 + GHK-Cu trio was located during this category research. [S2] [S11]

Direct evidence not located

Full KLOW

No primary human, animal or laboratory study of all four components together was located. [S17]

Direct evidence not located

“Not located” describes this research search, not proof that unpublished work cannot exist. It is enough to prevent claims that adding KPV has proven synergy, superior healing or improved safety.

GHK-Cu human evidence is topical and cannot validate KLOW

GHK-Cu contributes the strongest conventional human clinical evidence among the four KLOW ingredients, but it is route-specific. A randomized evaluator-blinded placebo-controlled diabetic-ulcer study reported improved plantar-ulcer closure with a topical GHK-Cu gel under standardized wound care. In a separate randomized post-CO2-laser study, 13 participants completed follow-up and objective measures showed no significant advantage for GHK-Cu on erythema, wrinkles or overall skin quality, although self-reported satisfaction was higher. Neither trial studied the KLOW blend or a co-lyophilised product. [S9] [S10]

GHK-Cu context	Finding	Why it does not validate KLOW
Diabetic neuropathic ulcers	Topical GHK-Cu gel improved several wound-closure measures versus vehicle under standardized care.	Different route, diagnosed population and no other KLOW components. [S9]
Post-CO2-laser skin care	No objective advantage on erythema, wrinkles or overall skin quality; higher patient satisfaction was reported.	Very small topical study and no co-formulated peptides. [S10]
Cosmetic / skin review literature	Mechanistic and older topical findings support continued research interest.	Narrative evidence cannot establish systemic KLOW efficacy. [S11]

Topical GHK-Cu evidence should not be turned into claims that KLOW rejuvenates skin, reverses ageing or improves wound healing by another route.

Relevant registered trials do not test KLOW

No verified ClinicalTrials.gov record for the exact KLOW mixture was located. The component landscape illustrates the evidence mismatch. NCT02637284 is an old BPC-157/Bepecin phase-1 safety and pharmacokinetics record with unknown status and no posted results. NCT02600429 is a phase-3 ophthalmic study of RGN-259 containing full-length thymosin beta-4, not the short TB-500 fragment. FDA's 2026 KPV review searched ClinicalTrials.gov and other databases and found no KPV clinical studies or human exposure data. [S6] [S17] [S27]

Registry / source	What was actually studied	Relevance to KLOW
NCT02637284	BPC-157 / Bepecin phase-1 safety and pharmacokinetics; unknown status; no posted results.	Single ingredient only. [S27]
NCT02600429	RGN-259 ophthalmic full-length thymosin beta-4 in neurotrophic keratopathy.	Different thymosin entity, route and no other KLOW components. [S6]
KPV	FDA's 2026 search found no clinical study or human exposure data.	No human KPV evidence to transfer into KLOW. [S17]
Exact KLOW mixture	No verified registry entry located in targeted searches.	No registered blend result available. [S17]

A registered study of one component or a related parent peptide is not a clinical trial of the four-component blend.

Co-formulating four compounds creates unanswered stability and compatibility questions

KLOW places several distinct chemical entities into one product: a 15-residue peptide, a TB-labelled thymosin-derived material, a copper-peptide complex and a three-residue melanocortin fragment. The studies cited here generally investigate these separately, or BPC-157 and TB-500 as a pair. No peer-reviewed study was located that characterises the chemical compatibility, degradation profile, copper-complex behaviour, stability or biological activity of the exact four-component mixture during storage or after preparation. FDA's KPV review also emphasises that peptide formulation, environmental conditions, aggregation and impurities can materially affect product quality. [S3] [S8] [S17]

KPV delivery matters

Nanoparticle/hydrogel KPV research changes targeting and exposure in animal models, showing why formulation-specific evidence cannot be ignored. [S16]

Formulation-specific

GHK-Cu is a metal complex

The claimed component is not simply free GHK; analytical verification should address the copper complex actually stated. [S7] [S8]

Chemical identity

Whole-blend stability

No peer-reviewed stability or compatibility study of the exact four-component KLOW mixture was located. [S17]

Evidence gap

Do not infer that four individually characterised ingredients remain chemically stable, correctly proportioned or biologically equivalent after co-formulation.

KLOW combination safety has not been established

There is no controlled human safety study of KLOW. Ingredient evidence is also incomplete. The BPC-157 systematic review found no clinical safety data in its included literature. FDA states that it has not identified human exposure data for KPV by any route and therefore cannot characterise human safety. FDA's current compounding safety page also raises peptide-quality and human-data concerns for several emerging peptide bulk substances. GHK-Cu topical data do not establish safety for another route. [S2] [S17] [S18]

BPC-157

Clinical safety remains inadequately characterised despite extensive animal literature. [S2]

Limited human safety data

KPV

FDA identified no human exposure data and states that potential human safety risks remain unknown. [S17] [S18]

No human exposure data identified

GHK-Cu

Human topical research cannot establish safety for a co-formulated research vial or another route. [S9] [S10]

Route-specific evidence

Four-way blend

No controlled human or long-term preclinical safety study of the exact KLOW mixture was located. [S17]

Not established

A high purity percentage does not establish sterility, endotoxin status, correct component identity, blend compatibility, long-term safety or suitability for human use.

KLOW versus GLOW: the extra component is KPV, not extra evidence

In the supplier market reviewed, GLOW is commonly BPC-157 + TB-500 + GHK-Cu, while KLOW adds KPV. That makes KPV the principal composition difference, but it does not make KLOW a studied upgrade to GLOW. KPV has preclinical anti-inflammatory research, yet FDA found no human exposure data, and no direct experiment was located comparing GLOW with KLOW. The names are commercial conventions, so each listing still requires independent quantity and identity checks. [S17] [S22] [S23] [S26]

Market name	Common composition observed	Evidence rule
GLOW	BPC-157 + TB-500 + GHK-Cu.	Treat as its own unvalidated three-component formulation. [S26]
KLOW	BPC-157 + TB-500 + GHK-Cu + KPV.	Adding KPV does not establish better efficacy, safety or anti-inflammatory outcomes. [S22] [S23] [S24] [S26]

Do not write “KLOW is GLOW plus anti-inflammatory benefits.” The defensible statement is only that KLOW adds KPV, a peptide with preclinical anti-inflammatory research.

UK regulatory and anti-doping context

MHRA's public product-information service is the official route for authorised-medicine information. Targeted searches for KLOW and its named components did not locate a UK-authorised KLOW medicinal product as of 2026-09-22. MHRA separately regulates specified routes for unlicensed medicines supplied for individual clinical need, which is not the same as a research-use blend holding a marketing authorisation. In sport, WADA's 2026 list prohibits BPC-157 under S0 and thymosin-β4 and its derivatives including TB-500 under S2.3. The absence of the word “KLOW” from the list does not override those component rules. [S19] [S20] [S21]

UK medicine status

No KLOW marketing-authorisation record was located in the targeted MHRA product-information search. [S20] [S21]

UK search finding

BPC-157 in sport

WADA lists BPC-157 under S0 non-approved substances, prohibited at all times. [S19]

Prohibited at all times

TB-500 / thymosin-β4 derivatives

WADA S2.3 explicitly includes thymosin-β4 and derivatives such as TB-500. [S19]

Prohibited at all times

No separate permission claim is made for GHK-Cu or KPV. Athletes should not infer that an unnamed substance is permitted merely because it is not individually listed.

How to interpret KLOW quantities and testing documentation

A single total quantity or purity figure does not fully describe a four-component blend. Several UK listings state 80 mg total with 50 mg GHK-Cu plus 10 mg each of BPC-157, TB-500 and KPV. Another UK page reviewed contained wording that was internally inconsistent with its stated 80 mg total, illustrating why product headings alone are not enough to compare quantities. Each component needs its own labelled amount, chemical identity, form and testing provenance. [S22] [S23] [S24] [S25]

Four component quantities

Store GHK-Cu, BPC-157, TB-labelled material and KPV amounts separately from the total blend mass. [S22] [S23] [S24]

Required

KPV form

Record free KPV, acetate or another modified/delivery form where disclosed. FDA treats free base and acetate as distinct bulk substances. [S12] [S17]

Form matters

TB-500 identity

A supplier label should not be treated as proof that the material is Ac-LKKTETQ or full-length thymosin beta-4. [S4] [S5]

Identity-critical

GHK-Cu verification

Testing should identify the copper complex claimed, not merely detect copper-free GHK. [S7] [S8]

Different chemistry

Field	What should be captured	What must not be inferred
Total blend mass	Supplier-labelled total per vial.	Amount of any individual ingredient. [S22] [S23] [S24]
BPC-157 amount	Explicit labelled or measured BPC-157 quantity.	One-quarter of the total. [S22] [S23] [S24]
TB-labelled amount / identity	Quantity plus exact thymosin-related identity if verified.	That 'TB-500' means full-length Tβ4 or Ac-LKKTETQ without evidence. [S4] [S5] [S22] [S23]
GHK-Cu amount / identity	Quantity and evidence for the copper complex.	That a GHK-only result verifies GHK-Cu. [S7] [S8] [S22] [S23]
KPV amount / form	Quantity plus free-acid, acetate or other form where known.	That all KPV forms and delivery systems are interchangeable. [S12] [S17] [S22] [S23]
Analytical report	Batch, lab, method, component identity, component assay and report date.	Clinical efficacy, sterility, safety or blend compatibility. [S17] [S22] [S23]

The existing single `quantity_mg` model is inadequate for KLOW. It needs component-level quantities and identity/testing records.

Frequently asked questions

What is in the KLOW blend?

The UK listings reviewed most commonly describe KLOW as GHK-Cu + BPC-157 + TB-500 + KPV. Several state 50 mg GHK-Cu and 10 mg of each other component, but KLOW is a commercial name, so composition must be verified product by product. [S22] [S23] [S24] [S25]

What is KPV?

KPV is the tripeptide Lys-Pro-Val, corresponding to α-melanocyte-stimulating hormone residues 11–13. PubChem records the free-acid form as H-Lys-Pro-Val-OH. [S12]

Has KPV been tested in humans?

FDA's 2026 review did not identify clinical studies or human exposure data for KPV free base or KPV acetate by any route. The evidence discussed here is therefore laboratory and animal evidence, not human clinical efficacy. [S17] [S18]

Does KPV prove that KLOW is anti-inflammatory in humans?

No. KPV reduced inflammatory signalling in cell systems and inflammatory measures in animal models, but that does not establish a human clinical effect, and the four-component KLOW blend itself has not been directly validated. [S13] [S14] [S15] [S17]

Has the complete KLOW blend been studied?

No primary human, animal or laboratory study of the exact BPC-157 + TB-500 + GHK-Cu + KPV mixture was located in the targeted searches for this review. Direct efficacy, synergy, compatibility and safety therefore remain unestablished. [S17]

Have any KLOW ingredients been studied together?

Yes. BPC-157 and TB-500 were directly tested together in a 2026 rat Achilles-tendon study. The authors reported no additional benefit from the two-peptide combination over either agent alone. GHK-Cu and KPV were not part of that experiment. [S3]

Is TB-500 the same as full-length thymosin beta-4?

No. Analytical work identified TB-500 material as the N-acetylated seven-residue fragment Ac-LKKTETQ, whereas full-length thymosin beta-4 is a different 43-residue peptide used in separate clinical programmes. [S4] [S5] [S6]

Is GHK-Cu the same as GHK?

No. GHK is the copper-free tripeptide Gly-His-Lys. GHK-Cu is a copper complex of that peptide and should be treated as a distinct analyte/formulation. [S7] [S8]

Does GHK-Cu research prove that KLOW improves skin or wound healing?

No. Human GHK-Cu findings located here involve topical wound or skin formulations. They do not establish the effectiveness of a four-component co-formulated research product. [S9] [S10] [S11]

What is the difference between KLOW and GLOW?

In the market reviewed, GLOW contains BPC-157, TB-500 and GHK-Cu, while KLOW adds KPV. This is a commercial naming convention, not evidence that KLOW is more effective or safer. [S22] [S23] [S26]

Is an 80 mg KLOW vial 80 mg of every ingredient?

No. The total refers to the combined labelled mass. Several UK suppliers state 50 mg GHK-Cu plus 10 mg each of BPC-157, TB-500 and KPV, which sums to 80 mg. [S22] [S23] [S24]

Does a 99% purity claim verify a KLOW blend?

Not by itself. A meaningful blend report needs to identify what was tested and whether each component was correctly identified and, where claimed, quantified. A headline purity percentage does not establish all four identities, sterility, safety or compatibility. [S17] [S22] [S23]

Is KLOW approved as a medicine in the UK?

Targeted MHRA product-information searches did not locate a UK-authorised KLOW medicinal product as of 22 September 2026. MHRA separately regulates certain unlicensed medicines, so this should not be expanded into a blanket legal claim about every research transaction. [S20] [S21]

Is KLOW prohibited in sport?

The blend contains components that are explicitly prohibited under current WADA rules: BPC-157 under S0 and thymosin-β4 and its derivatives including TB-500 under S2.3. The absence of the commercial name KLOW from the list does not override those component restrictions. [S19]

Sources & methodology

[S1] Bpc-157 | C62H98N16O22 | CID 9941957 ↗PubChem, National Library of Medicine / Chemical Database / Authority Page Read
[S2] Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review ↗HSS Journal / PubMed Central / Systematic Review / Full Text Read
[S3] Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study ↗Joint Diseases and Related Surgery / Preclinical Primary Study / Full Text Read
[S4] Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential ↗Drug Testing and Analysis / PubMed / Analytical Identity Study / Abstract Only
[S5] TB-500 | C38H68N10O14 | CID 62707662 ↗PubChem, National Library of Medicine / Chemical Database / Authority Page Read
[S6] Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1 ↗ClinicalTrials.gov / Trial Registry / Registry Read
[S7] glycyl-L-histidyl-L-lysine | C14H24N6O4 | CID 73587 ↗PubChem, National Library of Medicine / Chemical Database / Authority Page Read
[S8] Copper tripeptide | C14H21CuN6O4- | CID 139035031 ↗PubChem, National Library of Medicine / Chemical Database / Authority Page Read
[S9] Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper ↗Wound Repair and Regeneration / PubMed / Randomized Controlled Trial / Abstract Only
[S10] Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin ↗Archives of Facial Plastic Surgery / PubMed / Randomized Controlled Trial / Abstract Only
[S11] GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration ↗BioMed Research International / PubMed Central / Narrative Review / Full Text Read
[S12] Msh (11-13) | C16H30N4O4 | CID 125672 ↗PubChem, National Library of Medicine / Chemical Database / Authority Page Read
[S13] PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation ↗Gastroenterology / PubMed Central / Preclinical Primary Study / Full Text Read
[S14] Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease ↗Inflammatory Bowel Diseases / PubMed / Preclinical Primary Study / Abstract Only
[S15] Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides ↗Journal of Pharmacology and Experimental Therapeutics / PubMed / Preclinical Primary Study / Abstract Only
[S16] Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis ↗Molecular Therapy / PubMed Central / Preclinical Delivery Study / Full Text Read
[S17] FDA Evaluation of KPV-Related Bulk Drug Substances (KPV (Free Base) and KPV Acetate) ↗U.S. Food and Drug Administration / Regulatory Scientific Review / Full Text Read
[S18] Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks ↗U.S. Food and Drug Administration / Regulatory Safety Source / Authority Page Read
[S19] 2026 Prohibited List ↗World Anti-Doping Agency / Sport Authority / Authority Page Read
[S20] Find product information about medicines ↗Medicines and Healthcare products Regulatory Agency / Uk Regulatory Guidance / Authority Page Read
[S21] Supply unlicensed medicinal products (specials) ↗Medicines and Healthcare products Regulatory Agency / Uk Regulatory Guidance / Authority Page Read
[S22] KLOW - (GHK-CU, TB-500, BPC-157, KPV Blend) ↗Vanta Labs UK / Supplier Page / Full Text Read
[S23] KLOW Blend 80mg – BPC-157, TB-500, KPV, GHK-Cu | Research Peptides ↗UK Peptide Supply / Supplier Page / Full Text Read
[S24] KLOW Blend 80mg – GHK-Cu 50mg | BPC-157 10mg | TB500 10mg | KPV 10mg ↗Peptides of London / Supplier Page / Full Text Read
[S25] KLOW 80 mg — Four-peptide repair blend ↗Bioactive Labs / Supplier Page / Full Text Read
[S26] KLOW vs GLOW Peptide Blends: What's the Difference? ↗Flux Peptides / Supplier Editorial Page / Full Text Read
[S27] No Study Results Posted | NCT02637284 | PCO-02 - Safety and Pharmacokinetics Trial ↗ClinicalTrials.gov / Trial Registry / Registry Read

We separate animal models, observational human studies and ongoing trials. Scientific evidence is assessed independently of future supplier documentation. How we verify testing →

Page updated: 22 September 2026Sources checked: 22 September 2026

Testing evidence in this comparison

Testing claimed: 3
Verified independent evidence: 1

What does KLOW blend cost?

Lowest: £0.66 / mg · Median: £0.78 / mg · Highest: £0.94 / mg

KLOW Blend Research Peptides

Top Picks

Best Overall

KLOW 80mgUK Peptides (ukpeptides.org)

KLOW 80mg

Best Tested

KLOW 80mgUK Peptides (ukpeptides.org)

KLOW 80mg

Lowest Price per mg

KLOW Blend — 80 mgOwsa Labs

KLOW Blend — 80 mg

Compare research products

KLOW 80mgUK Peptides (ukpeptides.org)

KLOW 80mgReta Research

KLOW Blend 80mgPepSource

KLOW Blend — 80 mgOwsa Labs

What does the KLOW name refer to?

The four component identities must be verified separately

Individual ingredient research does not become KLOW evidence

BPC-157

TB-500

GHK-Cu

KPV

What KPV research does and does not establish

Cell models

Mouse colitis

Other inflammation models

Human outcomes

What is known about combinations containing KLOW ingredients?

BPC-157 + TB-500

KPV-containing KLOW pairs

GLOW trio

Full KLOW

GHK-Cu human evidence is topical and cannot validate KLOW

Relevant registered trials do not test KLOW

Co-formulating four compounds creates unanswered stability and compatibility questions

KPV delivery matters

GHK-Cu is a metal complex

Whole-blend stability

KLOW combination safety has not been established

BPC-157

KPV

GHK-Cu

Four-way blend

KLOW versus GLOW: the extra component is KPV, not extra evidence

UK regulatory and anti-doping context

UK medicine status

BPC-157 in sport

TB-500 / thymosin-β4 derivatives

How to interpret KLOW quantities and testing documentation

Four component quantities

KPV form

TB-500 identity

GHK-Cu verification

Frequently asked questions

Sources & methodology

Testing evidence in this comparison

What does KLOW blend cost?